Scarica l'app Stockscreener
44.91
7.59%
3.17
Dopo l'orario di chiusura:
44.70
-0.21
-0.47%
Precedente Chiudi:
$41.74
Aprire:
$42.02
Volume 24 ore:
5.09M
Relative Volume:
1.64
Capitalizzazione di mercato:
$8.50B
Reddito:
$2.83B
Utile/perdita netta:
$-1.02B
Rapporto P/E:
-8.1506
EPS:
-5.51
Flusso di cassa netto:
$194.14M
1 W Prestazione:
-4.26%
1M Prestazione:
-13.48%
6M Prestazione:
-11.23%
1 anno Prestazione:
-23.65%
Intervallo 1D:
$42.02
$45.45
Intervallo di 1 settimana:
$38.81
$45.45
Portata 52W:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Confronta EXAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
44.91 | 7.75B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
664.16 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
The Top 5 Analyst Questions From Exact Sciences’s Q2 Earnings Call - Yahoo Finance
Exact Sciences price target lowered to $60 from $65 at BTIG - TipRanks
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up - Yahoo Finance
BTIG lowers Exact Sciences stock price target to $60 on Freenome deal - Investing.com
EXAS Q2 Deep Dive: Portfolio Expansion and Productivity Drive Guidance Increase Amid Market Caution - Yahoo Finance
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock - Yahoo Finance
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 - Yahoo Finance
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
FY2025 EPS Forecast for Exact Sciences Increased by Analyst - Defense World
Applying Elliott Wave Theory to Exact Sciences CorporationEarnings Impact and Stock Reaction Analysis - Newser
How to read the order book for Exact Sciences CorporationFree Real Time Alerts Based on AI Prediction - Newser
Real time social sentiment graph for Exact Sciences CorporationAI Entry Timing Prediction for Swing Traders - Newser
Real time scanner hits for Exact Sciences Corporation explainedTrading Volume Anomaly Summary and Insight - Newser
Cathie Wood Buys Alphabet, Exact Sciences Amid Market Volatility - WebProNews
Avantax Advisory Services Inc. Acquires 1,259 Shares of Exact Sciences Corporation (NASDAQ:EXAS) - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Exact Sciences - Defense World
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $60 to $70 - 富途牛牛
Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock By Investing.com - Investing.com Australia
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock - Investing.com
Exact Sciences (NASDAQ:EXAS) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Exact Sciences Corp’s Strong Earnings Call Highlights - TipRanks
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst - AOL.com
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal? - Investor's Business Daily
Why Is Exact Sciences Stock Tumbling Thursday?Exact Sciences (NASDAQ:EXAS) - Benzinga
Exact Sciences Earnings: Blood-Based Test Misses Cutoff for Medicare Reimbursement - Morningstar
Exact Sciences Leads the Colorectal Cancer Screening Market, but Uncertainty Lies Ahead - Morningstar
Exact Sciences stock price target lowered to $46 at RBC on growth concerns - Investing.com Canada
Bernstein SocGen lowers Exact Sciences stock price target to $60 - Investing.com
Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Exact Sciences (EXAS) Secures Rights to Freenome's Cancer Screening Tests - GuruFocus
UBS Adjusts Exact Sciences Price Target to $53 From $61, Maintains Neutral Rating - MarketScreener
Research Alert: CFRA Lowers View On Shares Of Exact Sciences Corporation To Hold From Buy - 富途牛牛
Exact Sciences stock price target lowered to $66 by TD Cowen after blood test setback - Investing.com
Piper Sandler reiterates Overweight rating on Exact Sciences stock By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight rating on Exact Sciences stock - Investing.com
Exact Sciences Reports Strong Q2 2025 Revenue GrowthNews and Statistics - IndexBox
Exact Sciences Corp. Exceeds Q2 Earnings ExpectationsNews and Statistics - IndexBox
Exact Sciences price target lowered to $55 from $65 at Barclays - TipRanks
Exact Sciences Q2 2025 Earnings Call Transcript - MarketBeat
Exact Sciences to acquire US rights for Freenome’s blood-based CRC test - Yahoo Finance
Exact Sciences: Q2 Earnings Snapshot - Manistee News Advocate
Earnings call transcript: Exact Sciences Q2 2025 beats EPS forecasts - Investing.com
Exact Sciences Q2 2025 slides: Revenue jumps 16%, guidance raised on strong performance - Investing.com Canada
Exact Sciences Corp. Reports Strong Q2 2025 Results - TipRanks
Exact Sciences lays off 4% of company including Madison positions - WMTV 15 NEWS
Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer | Newswise - Newswise
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Exact Sciences (EXAS) Q2 Revenue Up 16% - The Globe and Mail
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2% - Yahoo Finance
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exact Sciences Corp Azioni (EXAS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Aug 05 '25 |
Option Exercise |
0.00 |
5,350 |
0 |
27,943 |
3.96%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):